About CTI Science
CTI Science is a Healthcare company based in Lexington (United States) founded in 2007, and was acquired by EmeraMed in July 2014. Focused on the development of therapeutics for the treatment of drug toxicity. CTI Science has raised $3.97 million across 2 funding rounds from investors including EmeraMed. CTI Science offers products and services including Emeramide and Early Access Program. Its focus areas include Diversified Pharmaceuticals. Its legal entity is EmeraMed Ltd.
Company details
CTI Science, formerly known as Chelator Technologies produces dietary antioxidants that maintain healthy glutathione levels in the body. They developed OSR1 which is an antioxidant product that scavenges free radicals and helps maintain healthy glutathione levels. Pharmacies halted the sales of this product six weeks after the U.S. Food and Drug Administration called the product an unapproved new drug.The company was later acquired by ERMES Medical in July 2014.
Products & Services of CTI Science
CTI Science offers a comprehensive portfolio of products and services, including Emeramide and Early Access Program.
A drug that chelates heavy metals and reduces oxidative stress in the body.
Program providing access to Emeramide for patients before full approval.
Apps and channels of CTI Science
its YouTube channel EmeraMed has 291 subscribers and 2 videos.
Videos from CTI Science
The most watched videos on CTI Science's YouTube channel, EmeraMed (291 subscribers). Click a video to play it here.
More on EmeraMed.
Funding Insights of CTI Science
CTI Science has successfully raised a total of $3.97M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $271 thousand completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.97M
- Total Rounds 2
- Last Round Series A — $271,000
- First Round $3.7M
(Oct 2013)
All 2 funding rounds of CTI Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2014 | $271,000 | Series A | – | – | – |
| Oct 2013 | $3.7M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in CTI Science
CTI Science has secured backing from 1 investor. Prominent investors backing the company include EmeraMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for mercury toxicity treatment are developed by EmeraMed. | 2007 | emeramed.com | Dublin, Ireland |
Investor details for CTI Science
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CTI Science
4 dated milestones of CTI Science across 7 years, from founding to its latest funding, stage changes and deals.
- Founded CTI Science is founded.
- Funding First funding round of $3.7M.
- Funding Latest funding round, Series A, of $271K.
- Exit Acquired by EmeraMed.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as CTI Science (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CTI Science
CTI Science was founded in 2007 and raised its 1st funding round 6 years after it was founded.
CTI Science is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
CTI Science is a funded company, having raised a total of $3.97M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.7M, raised on Oct 2013.
CTI Science, formerly known as Chelator Technologies produces dietary antioxidants that maintain healthy glutathione levels in the body. They developed OSR1 which is an antioxidant product that scavenges free radicals and helps maintain healthy glutathione levels. Pharmacies halted the sales of this product six weeks after the U.S. Food and Drug Administration called the product an unapproved new drug.The company was later acquired by ERMES Medical in July 2014.
CTI Science offers Emeramide and Early Access Program.
CTI Science has 1 investor. Key investors include EmeraMed.
CTI Science operates through Emeramed Ltd.
Yes. CTI Science was acquired by EmeraMed in July 2014.